Oasmia Pharmaceutical AB publ announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was SEK 4.596 million compared to SEK 254,000 a year ago. Operating loss was SEK 56.165 million compared to SEK 78.296 million a year ago. Net loss was SEK 57.677 million compared to SEK 80.090 million a year ago. Basic loss per share from continuing operations was SEK 0.12 compared to SEK 0.18 a year ago. For the half year, sales was SEK 4.633 million compared to SEK 2.140 million a year ago. Operating loss was SEK 97.007 million compared to operating Income of SEK 50.311 million a year ago. Net loss was SEK 98.886 million compared to net income of SEK 44.602 million a year ago. Basic loss per share from continuing operations was SEK 0.22 compared to basic earnings per share from continuing operations of SEK 0.1 a year ago.